Results 51 to 60 of about 216,339 (397)
Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment [PDF]
, 2019 Oxidation of monoclonal antibodies (mAbs) can impact their efficacy and may therefore represent critical quality attributes (CQA) that require evaluation.
Dyck, Yan Felix Karl +6 more
core +1 more source
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
Hepatology, EarlyView., 2022 In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie +17 more
wiley +1 more source
A five arm natural history study of nasal vestibulitis
Cancer Medicine, 2023 Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake +11 more
doaj +1 more source
Veterinary Sciences, 2023 Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to ...
Ulrike Lessiak +3 more
doaj +1 more source
American Journal of Neuroradiology, 2009 Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire +2 more sources
Regulatory withdrawal of medicines marketed with uncertain benefits : the bevacizumab case study [PDF]
, 2015 Acknowledgements Professor Elizabeth Roughead is funded by a Future Fellowship from the Australian Research Council. The views expressed are those of the authors, the sponsor had no role in the preparation of the manuscript.Peer reviewedPublisher ...
Entwistle, Vikki +3 more
core +1 more source
JAMA Oncology, 2021 This randomized clinical trial assesses the efficacy and safety of osimertinib plus bevacizumab vs osimertinib alone in patients with EGFR T790M–mutated lung adenocarcinoma.
H. Akamatsu +16 more
semanticscholar +1 more source
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]
, 2013 BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel +11 more
core +2 more sources
Bevacizumab and corneal pathology
Medicina fluminensis, 2017 Cilj rada je dati pregled postojeće literature o terapiji bevacizumabom u liječenju neovaskularnih poremećaja rožnice. Rožnica je jedinstveno tkivo zbog svoje prirodne avaskularnosti. Imunoprivilegirano je vezivno tkivo koje služi kao mehanička prepreka i prednja refraktivna površina oka.
Bilen Babić, Marijana, Merlak, Maja
openaire +4 more sources
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy [PDF]
, 2019 The therapeutic management of recurrent malignant gliomas (MGs) is not determined. Therefore, the efficacy of a multimodal approach and a combination systemic therapy was investigated.
Bianco, Vincenzo +10 more
core +1 more source